obt076
mAbexperimentalADC
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 25, 2019 (NCT04064359)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Lymphocyte antigen 75INHIBITOR
LY75 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- Ravtansine
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05930951 | Phase 1 | Nov 29, 2023 | Groupe Oncologie Radiotherapie Tete et Cou |
| NCT04064359 | Phase 1 | Jul 25, 2019 | Columbia University, Oxford BioTherapeutics Ltd |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Columbia University | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Groupe Oncologie Radiotherapie Tete et Cou | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Oxford BioTherapeutics Ltd | For profit | 1 | 1 | 1 | 2019 |
3 organizations
Page 1 / 1